A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. - Wikidata - awgldk - TriplyDB

A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer.

A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer.

http://www.wikidata.org/entity/Q33267359

about

Molecular and therapeutic potential and toxicity of valproic acid Identification of cells initiating human melanomas A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma Epigenetic treatment of solid tumours: a review of clinical trials Stem cells and targeted approaches to melanoma cure Trials with 'epigenetic' drugs: an update PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2 Epigenetic regulation in estrogen receptor positive breast cancer--role in treatment response ABCB5 maintains melanoma-initiating cells through a proinflammatory cytokine signaling circuit Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial Molecular evolutionary analysis of ABCB5: the ancestral gene is a full transporter with potentially deleterious single nucleotide polymorphisms DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells Term-tissue specific models for prediction of gene ontology biological processes using transcriptional profiles of aging in drosophila melanogaster.The therapeutic promise of the cancer stem cell concept.A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC.Response to hydralazine-valproate in a patient with mycosis fungoides Identification and targeting of cancer stem cells.A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results.Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial).Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.Augmenting antitumor immune responses with epigenetic modifying agents.Wnt5A regulates ABCB1 expression in multidrug-resistant cancer cells through activation of the non-canonical PKA/β-catenin pathway Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer A genomic approach to predict synergistic combinations for breast cancer treatment The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study Advances in breast cancer: pathways to personalized medicine Role of epigenetic modifications in luminal breast cancer.Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.Epigenetic Therapy in Breast Cancer.p16INK4a gene promoter hypermethylation in mucosa as a prognostic factor for patients with colorectal cancer.Epigenetic suppression of neprilysin regulates breast cancer invasion Serine/threonine kinases 31(STK31) may be a novel cellular target gene for the HPV16 oncogene E7 with potential as a DNA hypomethylation biomarker in cervical cancer.Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression.Effect of sodium valproate on the toxicity of cyclophosphamide in the testes of mice: influence of pre- and post-treatment schedule Epigenomics and breast cancer Targeting histone deacetylases for the treatment of disease Valproic Acid, a Histone Deacetylase Inhibitor, in Combination with Paclitaxel for Anaplastic Thyroid Cancer: Results of a Multicenter Randomized Controlled Phase II/III Trial.Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.Role of epigenetics in chronic myeloid leukemia Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials.

P2860

Q21296867-E624D600-BBC8-4BFD-8755-E320CA2FB694 Q24622896-CA568819-0BFF-4D33-BDD0-412E82BFE7AA Q24658533-78472288-BCFC-46D8-A6B0-95F859EF1CB1 Q26773803-83D59BB0-C849-45B4-A010-E0AB02B23F96 Q26825014-0858A2F0-65C3-4BF3-B278-696746E19DA5 Q27000542-52F74470-BC71-4BF6-8C8A-61FBEE1D034A Q27011622-877E2E76-D78C-4354-A2C9-92C0248C57FD Q27694612-EAF4B7DC-04EA-4609-A3B1-986D13FD4CE9 Q28242049-2826F519-4B42-47ED-9A6D-D6B73D89FA2F Q28294892-3844D732-9345-4C3B-8FD0-EC2FE14FF0F0 Q28476833-02CD7B12-6260-4571-8500-3E1D1820F284 Q28481440-5C530C52-CA2D-4B16-8259-092B102697C0 Q33321696-5EF5AF64-8B87-4047-A4F2-032879C4942E Q33559711-3C1E55CE-EB10-4D81-9C51-F270DAA9565E Q33689457-4CCD2859-1ED1-41DE-BA21-74DEA06C23FA Q33743913-7BD7E03E-AA40-4037-BC35-A56B8CE8B3F1 Q33921460-C98BC9A0-5990-4AB1-8ED2-2A5F1C9A211C Q34142430-A8312ADF-9215-4817-913E-CF6570352951 Q34898391-D816BA6D-E9DE-4002-9FA1-EF4E5E84563F Q35000789-A546B659-4DD8-4E37-A511-01E88DD511B1 Q35048054-89B0AF3C-C9F8-4F08-BADB-D64F0152E7D8 Q35067970-0CD3145B-3B7E-41AD-9CE6-BC6C27A191DD Q35079955-CDA5DDBA-86DC-418F-9302-10C948657D11 Q35670293-980EB242-336E-46EA-BC13-2F96A061283C Q35674823-14058CBE-B2E0-4A7D-8885-920FAE9D7D34 Q35951346-912F95A3-985E-4683-A248-AAB189DC8C75 Q35963443-A7DD2E42-9650-4A57-8345-F1999A57001E Q36203560-42362688-7E80-4697-88CD-2F9B5A622BA2 Q36337694-690526E7-BF9E-474E-A56D-8EE227583A5A Q36556548-7EE4E7AB-60EA-4A3C-8EE4-31D89ADE1000 Q36748694-6894DE2A-9307-49D6-9C62-2E62819BA121 Q36765309-61E54DE8-3A98-46BA-AAA2-0D7CADA80E70 Q36946596-788E1108-C81E-47D6-8FCB-7EBA3B67D8E3 Q36984572-60367C79-D9CB-427F-9002-344C9764E92F Q37078784-8663DCD6-CE3A-4572-8B26-5B1EF87DEE2E Q37296159-15A5EE58-3A48-450F-A5C3-CA9EB220A269 Q37330090-654F7CF5-010F-4562-A842-2310AEA769A1 Q37445211-C03F3920-25A7-4244-B9EA-63E1BB19F47F Q38072315-EE8E2EAA-3780-4971-9AC1-80BC5BD50394 Q38081988-544553FC-8B7D-44FE-8545-2B2991176C1C

P2860

A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer.

http://www.wikidata.org/entity/Q33267359

description

2006 nî lūn-bûn

@nan

2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

A proof-of-principle study of ...... ocally advanced breast cancer.

@ast

A proof-of-principle study of ...... ocally advanced breast cancer.

@en

A proof-of-principle study of ...... ocally advanced breast cancer.

@nl

type

label

A proof-of-principle study of ...... ocally advanced breast cancer.

@ast

A proof-of-principle study of ...... ocally advanced breast cancer.

@en

A proof-of-principle study of ...... ocally advanced breast cancer.

@nl

prefLabel

A proof-of-principle study of ...... ocally advanced breast cancer.

@ast

A proof-of-principle study of ...... ocally advanced breast cancer.

@en

A proof-of-principle study of ...... ocally advanced breast cancer.

@nl

P1433

Q33267359-9D0EE7CA-489D-4159-8D54-986F7D6B8554

P1476

Q33267359-E36CC1A6-62C7-42C4-9B6D-52C47FE22E39

P2093

Q33267359-16AE8E56-1642-4BC9-A584-5ADE6F5A9FDA

Q33267359-2D81F51A-393B-4C44-8F29-94D010E66D9F

Q33267359-4EDA29AA-7A92-4719-BD81-96BC5137B37E

Q33267359-5812997A-D7D2-4F8E-BF52-DD01796CA608

Q33267359-6522C84D-9347-4B21-AB63-9012E309A3D3

Q33267359-69EAB5B2-F0C0-4EB1-93EC-625AA54D8689

Q33267359-8ABF6707-B2A7-4C23-90BC-4401550F851A

Q33267359-8C25A381-FD49-4D3A-A84D-808867A35CD0

Q33267359-94035C9D-B610-4FF1-8AAB-0EB4D5D7DBF5

Q33267359-9748BE97-4B0F-45EC-A83C-397CA6CB5647

P2860

Q33267359-0448E73A-DE48-4B23-8FD9-DA7368BE2A49

Q33267359-0A3C8F15-53F6-4DB7-ABD0-3DB437A2AC46

Q33267359-0D42B47A-0362-47DE-BCA2-43CEC4DF75B3

Q33267359-1020B12A-B051-4AFE-8C99-95C02EFC4F55

Q33267359-154FAA32-DE4C-4BAE-81DE-E3F245AE5C55

Q33267359-1AA1FA2C-5AB8-46B0-A06C-01CAF72E4431

Q33267359-1DFF952A-68D7-489C-918E-B22C72B3FD31

Q33267359-2E85F7FA-A0A8-4702-B967-203FE63FB6AC

Q33267359-36633270-A195-4052-BB33-8E033DEDEC45

Q33267359-3CD9FCD1-C081-44DB-A90E-7BA708EB9294

P304

Q33267359-7A97D63E-36ED-495E-B4EA-8267ACF80E94

P31

Q33267359-27E8D43A-4041-4593-878B-AAF057798070

P356

Q33267359-09894AEE-5430-48FB-8E8F-FCFA4C16D3C2

P407

Q33267359-7C3A2892-442B-4ACA-90D8-F7B4EB1F9B05

P478

Q33267359-1469D412-3467-48BC-846C-042C19E42968

P50

Q33267359-6B76DCA3-C8AD-4EBD-82DC-7015812C16E2

P577

Q33267359-383C8CE1-8FF5-4A16-B87B-63AD9758A7B1

P5875

Q33267359-764599F2-16FB-4D7A-BEA9-C5739AF9108A

P698

Q33267359-82E6A8D3-1252-47D4-81AA-2549B2C68AF3

P932

Q33267359-68418398-1CEF-4C60-9895-E6366077B3C2

P356

JOURNAL.PONE.0000098

P1433

P1476

A proof-of-principle study of ...... ocally advanced breast cancer.

@en

P2093

Alfonso Dueñas-González

http://www.w3.org/2001/XMLSchema#string

Alma Chávez-Blanco

http://www.w3.org/2001/XMLSchema#string

Alma Revilla-Vázquez

http://www.w3.org/2001/XMLSchema#string

Aurora González-Fierro

http://www.w3.org/2001/XMLSchema#string

Carlos Pérez-Plasencia

http://www.w3.org/2001/XMLSchema#string

Catalina Trejo-Becerril

http://www.w3.org/2001/XMLSchema#string

Claudia Arce

http://www.w3.org/2001/XMLSchema#string

Elizabeth Robles

http://www.w3.org/2001/XMLSchema#string

Enrique Bargallo

http://www.w3.org/2001/XMLSchema#string

Enrique Pérez-Cárdenas

http://www.w3.org/2001/XMLSchema#string

P2860

GRIM-19, a cell death regulatory protein, is essential for assembly and function of mitochondrial complex I

Significance analysis of microarrays applied to the ionizing radiation response

A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes

Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study

Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines.

ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

Genesis: cluster analysis of microarray data

Hematologic toxicity of sodium valproate.

Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity.

P304

e98

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0000098

http://www.w3.org/2001/XMLSchema#string

P407

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

Carlos Pérez-Plasencia

P577

2006-12-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6616183

http://www.w3.org/2001/XMLSchema#string

P698

17183730

http://www.w3.org/2001/XMLSchema#string

P932

1762324

http://www.w3.org/2001/XMLSchema#string